PRAZIMED Trademark

Trademark Overview


On Monday, February 12, 2024, a trademark application was filed for PRAZIMED with the United States Patent and Trademark Office. The USPTO has given the PRAZIMED trademark a serial number of 98402378. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, October 15, 2024. This trademark is owned by Right2Try Inc. The PRAZIMED trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical compositions and medicaments for use in treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the proliferation, metastasis and angiogenic activity of malignant cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, regulation of one or more kinase signaling pathway, reversing multi-drug resistance, inhibiting tumor stem cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, providing anti-inflammatory and antiviral properties; Pharmaceutical compositions and medicaments for use in the treatment of cancer
prazimed

General Information


Serial Number98402378
Word MarkPRAZIMED
Filing DateMonday, February 12, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, October 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 15, 2024

Trademark Statements


Goods and ServicesPharmaceutical compositions and medicaments for use in treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the proliferation, metastasis and angiogenic activity of malignant cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, regulation of one or more kinase signaling pathway, reversing multi-drug resistance, inhibiting tumor stem cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, providing anti-inflammatory and antiviral properties; Pharmaceutical compositions and medicaments for use in the treatment of cancer
In Another Form StatementThe mark was first used anywhere in a different form other than that sought to be registered at least as early as
In Another Form StatementThe mark was first used anywhere in a different form other than that sought to be registered at least as early as

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 12, 2024
Primary Code005
First Use Anywhere DateMonday, January 1, 2024
First Use In Commerce DateMonday, January 1, 2024

Trademark Owner History


Party NameRight2Try Inc
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLewes, DE 19958

Party NameRight2Try Inc
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLewes, DE 19958

Trademark Events


Event DateEvent Description
Monday, February 12, 2024NEW APPLICATION ENTERED
Wednesday, June 12, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 5, 2024ASSIGNED TO EXAMINER
Friday, September 6, 2024NON-FINAL ACTION WRITTEN
Friday, September 6, 2024NON-FINAL ACTION E-MAILED
Friday, September 6, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 10, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 10, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 10, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 10, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 25, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 15, 2024PUBLISHED FOR OPPOSITION
Tuesday, October 15, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED